https://www.selleckchem.com/products/bda-366.html
and socio-economic inequities. The COVID-19 pandemic has highlighted the threat of emerging respiratory viruses and has exposed the lack of availability of off-the-shelf therapeutics against new RNA viruses. Previous research has established the potential that siRNAs and RNA-targeting CRISPR have in combating known RNA viruses. However, the feasibility and tools for designing anti-viral RNA therapeutics against future RNA viruses have not yet been established. We develop the Evitar (Emerging-Virus-Targeting RNA) pipeline for designing a
Gefällt mir
Kommentar
Teilen
